Benign Prostatic Hyperplasia (Investigational Adjunct)
Investigational adjunct for symptomatic benign prostatic hyperplasia; alpha-blockers, 5-alpha-reductase inhibitors, and minimally invasive surgical therapy remain evidence-based.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for benign prostatic hyperplasia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
- What evidence exists?
- Tier C (investigational). Only one Russian observational report (about 200 men with BPH treated with leeches plus standard care, published 1998 and not indexed in PubMed) was found, and it gives no BPH-specific symptom results; no randomized trials were identified. Evidence-based first-line therapy per AUA is alpha-blockers (tamsulosin, alfuzosin, silodosin) for symptom relief, 5-alpha-reductase inhibitors (finasteride, dutasteride) for prostate-volume reduction in larger glands, and combination therapy for moderate-to-severe disease. PDE5 inhibitors (tadalafil) help with concurrent erectile dysfunction. Minimally invasive surgical therapies (TURP, holmium laser enucleation, GreenLight laser, UroLift, Rezum, prostatic artery embolization) are highly effective and well-evidenced for medical-refractory disease.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the suprapubic or perineal area for 5 to 10 days
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Temporary worsening of urinary symptoms for 1 to 3 days
- Risk of orthostasis or hypotension if cumulative blood loss is significant on alpha-blocker therapy
- Delay or replacement of evidence-based alpha-blocker, 5-alpha-reductase inhibitor, or minimally invasive surgery
- Failure to address acute retention, recurrent UTI, hematuria, or bladder stones requiring surgical evaluation
- Who should not consider this
- Patients in acute urinary retention (surgical / catheter management indicated)
- Patients with recurrent UTI attributable to BPH
- Patients with hematuria that has not been worked up
- Patients with bladder stones, hydronephrosis, or renal insufficiency from BPH (surgical indication)
- Patients with suspected prostate cancer (PSA / DRE workup first)
- Patients on anticoagulants, with hemophilia, or with anemia
- What to ask your clinician
- What is my IPSS (International Prostate Symptom Score) and bother score?
- Has my PSA been checked, and is prostate cancer ruled out?
- Have I had post-void residual measurement, uroflowmetry, and (where indicated) bladder ultrasound?
- Have I tried alpha-blockers (tamsulosin)? Have 5-alpha-reductase inhibitors been considered if the gland is enlarged?
- Am I a candidate for minimally invasive surgery (UroLift, Rezum, TURP, HoLEP, GreenLight)?
- Where exactly will leeches be placed — NEVER trans-rectal?
- What is the practitioner's experience and Aeromonas-prevention plan?
- When to seek urgent care
- Inability to urinate (acute urinary retention — urgent care)
- Visible blood in urine, especially with clots
- Severe lower abdominal pain with distended bladder
- Fever, chills, dysuria, flank pain (UTI or pyelonephritis)
- Sudden urinary leakage (overflow incontinence)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
What this does NOT mean
- It has not been shown to shrink the prostate; 5-alpha-reductase inhibitors have RCT evidence for that in larger glands.
- It does not replace alpha-blockers for symptom relief, which have strong RCT support.
- It does not address acute urinary retention, recurrent UTI, hematuria, or bladder stones, all of which need surgical referral.
- Only one Russian observational report was found and it gives no BPH-specific symptom results, so benefit is unproven.
Safety cross-references
Clinical Profile
- Category
- Urogenital
- ICD-10
- N40.0, N40.1, N40.3
- Safety tier
- Medium
Evidence Summary
Symptomatic benign prostatic hyperplasia (BPH) presents with lower urinary tract symptoms (LUTS): frequency, urgency, weak stream, nocturia, and incomplete emptying. AUA evidence-based first-line pharmacotherapy is alpha-blockers (tamsulosin, alfuzosin) for symptom relief, 5-alpha-reductase inhibitors (finasteride, dutasteride) for gland-volume reduction in larger prostates, combination therapy for moderate-severe disease, and PDE5 inhibitors (tadalafil) for concurrent erectile dysfunction. Minimally invasive surgical therapy (TURP, GreenLight laser, UroLift, Rezum) is highly effective for medical-refractory disease. No randomized trial of hirudotherapy for benign prostatic hyperplasia was identified in PubMed, Europe PMC, Crossref, or ClinicalTrials.gov. The only clinical report found is a Russian observational series (Savinov and Kuchersky 1998, as summarized in Baskova and Isakhanyan 2004): 209 men with BPH and 151 with chronic prostatitis received leeches alongside conventional treatment; the monograph reports better prostate drainage and more cures in prostatitis, and cites a comparison group of 669 patients only for prostate-cancer incidence over 7 years, but it gives no symptom-score, urinary-flow, or prostate-volume results for BPH, and the original report is not indexed in PubMed. Any use is investigational only, and the mechanism for any deep prostatic effect from skin placement is speculative.
What the books describe
Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.
- Baskova and Isakhanyan name prostate adenoma among the diseases for which, according to their list, treatment with leeches is recommended[B1].
- They retell an observation by Savinov and Kucherskiy (1998): among the patients were 209 with prostate adenoma (and 151 with chronic prostatitis), who received leeches in addition to the usual treatment; the retelling says that the method “proved effective,” the drainage function of the gland improved and the number of cures increased[B1].
- The book does not give results specifically for adenoma (for example, changes in urination or in the size of the gland): in the reference list, Savinov and Kucherskiy are credited with the works “Hirudotherapy in the combined treatment of patients with chronic prostatitis” and “The role of hirudotherapy in cancer prevention,” and elsewhere in the book the improvement in drainage function and the rise in cures are mentioned only for chronic prostatitis[B1].
- Baskova and Isakhanyan write that the role of hirudotherapy in cancer prevention is “examined in detail and substantiated” by Savinov (1993), and they cite an observation by Savinov and Kucherskiy (1998): over 7 years, among 151 patients with chronic prostatitis and 209 patients with adenoma no prostate cancer was detected, while in a comparison group (253 patients with prostatitis and 416 patients with adenoma) cancer was confirmed 21 times over the same period; the observed patients were prescribed immunomodulators and other agents, “less often” hormones and leeches, so it is not clear from the text how many patients received leeches or how the groups were formed[B1].
- Baskova and Isakhanyan call V. A. Savinov a consistent advocate of leeches in urology, but in another chapter they agree with criticism according to which the technologies proposed by him (among other authors) “do not withstand any criticism” from the standpoint of “true naturopathy” and the principle “do no harm” (whether this applies to his urological method is not clear from the text), and in the chapter on contraindications they write that prescribing leeches “in large numbers, for long periods, with no or only short breaks” is unjustified and impermissible[B1].
- Michalsen et al. do not write about prostate adenoma.
- Both books name hemophilia, taking anticoagulants (medicines that affect blood clotting) and anemia as contraindications: Baskova and Isakhanyan include them in their general list of contraindications, while Flecken and Michalsen, in the chapter on contraindications, call hemophilia and anticoagulants an absolute contraindication and regard treatment involving blood loss as generally contraindicated in anemia; this is only part of the contraindications listed in the books[B1][B3].
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Acute urinary retention (surgical referral)
- Recurrent UTI from BPH
- Hematuria not worked up
- Bladder stones, hydronephrosis, or renal insufficiency from BPH (surgical indication)
- Suspicion of prostate cancer (PSA, DRE workup first)
Related Conditions
Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)
Investigational for category III CP/CPPS: evidence is limited to a 3-patient case report, an uncontrolled Russian series and a comparison in urogenital infection; multimodal therapy remains standard.
Prostatic Calculi (Investigational Adjunct)
Investigational adjunct for symptomatic prostatic calculi associated with chronic prostatitis; targeted antibiotics, alpha blockers, and selective transurethral resection remain evidence-based.
Peyronie's Disease (Stable Phase)
Investigational use for stable-phase Peyronie's disease; evidence limited to one uncontrolled Russian series of 29 patients. Standard treatments (verapamil, collagenase, surgery) remain first-line.
Interstitial Cystitis / Bladder Pain Syndrome (Investigational)
Highly investigational adjunct for IC/BPS refractory to conventional therapy; no clinical study identified; AUA-guideline stepwise therapy remains primary.
References
- [B1]
Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]
Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.
- [B3]
Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy
ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.
The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.